全文获取类型
收费全文 | 188篇 |
免费 | 26篇 |
国内免费 | 2篇 |
专业分类
基础医学 | 14篇 |
口腔科学 | 8篇 |
临床医学 | 10篇 |
内科学 | 7篇 |
神经病学 | 2篇 |
特种医学 | 4篇 |
外科学 | 96篇 |
综合类 | 5篇 |
预防医学 | 3篇 |
药学 | 25篇 |
肿瘤学 | 42篇 |
出版年
2023年 | 7篇 |
2022年 | 10篇 |
2021年 | 23篇 |
2020年 | 17篇 |
2019年 | 23篇 |
2018年 | 17篇 |
2017年 | 8篇 |
2016年 | 9篇 |
2015年 | 5篇 |
2014年 | 9篇 |
2013年 | 15篇 |
2012年 | 8篇 |
2011年 | 8篇 |
2010年 | 6篇 |
2009年 | 8篇 |
2008年 | 9篇 |
2007年 | 8篇 |
2006年 | 3篇 |
2005年 | 8篇 |
2004年 | 3篇 |
2003年 | 3篇 |
2002年 | 2篇 |
2001年 | 1篇 |
1999年 | 1篇 |
1997年 | 3篇 |
1996年 | 1篇 |
1983年 | 1篇 |
排序方式: 共有216条查询结果,搜索用时 15 毫秒
1.
2.
人β防御素-2与前列腺癌特异性膜抗原嵌合蛋白真核表达质粒构建及其诱导的小鼠特异性免疫应答 总被引:2,自引:0,他引:2
探索人β防御素2 (h BD- 2 )和前列腺特异性膜抗原(PSMA)共表达重组核酸疫苗针对前列腺癌的免疫治疗。研究以pc DNA3.1为载体,构建重组质粒pc DNA3.1/PSMA和pc DNA3.1/h BD- 2 - PSMA,通过RT- PCR和免疫组化检测其表达。免疫小鼠后,进行血清中抗体检测,CD4 、CD8 T淋巴细胞数目测定及CTL 特异性杀伤作用检测。结果显示构建的质粒转染COS- 7细胞后能表达目的基因,免疫小鼠后能在体内持久表达,可以诱导产生特异性抗体,能有效的刺激T细胞增生,诱导特异性CTL 反应。当以h BD- 2作为免疫佐剂时,CTL 活性更强。本研究成功的构建了含PSMA的表达质粒,免疫小鼠可以诱导出有效的体液和细胞免疫,为前列腺癌的免疫治疗奠定了一定的实验基础 相似文献
3.
表达前列腺特异性膜抗原的DNA疫苗对肿瘤细胞的抑制作用 总被引:3,自引:0,他引:3
目的构建表达前列腺特异性膜抗原(PSMA)的DNA疫苗,观察其在体外对肿瘤细胞的免疫攻击和在体内对肿瘤细胞攻击的免疫保护作用。方法通过稳定转染构建表达PSMA的小鼠黑色素瘤细胞系B16-PSMA,将DNA疫苗pCDNA3.1-PSMA通过肌肉注射导入C57BL/6小鼠体内,分离小鼠脾细胞,检测细胞毒性T淋巴细胞(cytotoxic T lymphocytes,CTL)反应。以B16-PSMA细胞攻击免骺小鼠,观察免疫动物的无瘤生存期和肿瘤体积增长情况,评价DNA疫苗的抗肿瘤作用。结果DNA疫苗可诱导小鼠脾淋巴细胞CTL活性,经过免疫后的小鼠成瘤率降低,无瘤生存期延长,肿瘤生长缓慢,肿瘤组织内有较多淋巴细胞浸润,表明产生较强的抗肿瘤反应。结论表达PSMA的DNA疫苗能够诱导小鼠产生特异性免疫反应,对表达PSMA的肿瘤细胞的攻击产生免疫保护作用,为前列腺癌的预防和免疫治疗提供了新的思路。 相似文献
4.
5.
6.
There is a need for developing improved therapeutic options for the management of prostate cancer, able to inhibit proliferation of precancerous and malignant lesions and/or to improve the effectiveness of conventional chemopreventive and chemotherapeutic agents. In this perspective, application of nanotechnology based strategies for the delivery of natural compounds for effective management of the disease is being actively researched. Here, after highlighting the most promising natural compounds for chemoprevention and chemotherapy of prostate cancer, the state of the art nanotherapeutics and the recent proof-of-concept of “nanochemoprevention”, as well as the clinical development of promising targeted nanoprototypes for use in the prostate cancer treatment are being discussed. 相似文献
7.
《Vaccine》2015,33(41):5386-5395
The goal of this study was to determine if an alphavirus-based vaccine encoding human Prostate-Specific Antigen (PSA) could generate an effective anti-tumor immune response in a stringent mouse model of prostate cancer. DR2bxPSA F1 male mice expressing human PSA and HLA-DRB1*1501 transgenes were vaccinated with virus-like particle vector encoding PSA (VLPV–PSA) followed by the challenge with Transgenic Adenocarcinoma of Mouse Prostate cells engineered to express PSA (TRAMP–PSA). PSA-specific cellular and humoral immune responses were measured before and after tumor challenge. PSA and CD8 reactivity in the tumors was detected by immunohistochemistry. Tumor growth was compared in vaccinated and control groups. We found that VLPV–PSA could infect mouse dendritic cells in vitro and induce a robust PSA-specific immune response in vivo. A substantial proportion of splenic CD8 T cells (19.6 ± 7.4%) produced IFNγ in response to the immunodominant peptide PSA65–73. In the blood of vaccinated mice, 18.4 ± 4.1% of CD8 T cells were PSA-specific as determined by the staining with H-2Db/PSA65–73 dextramers. VLPV–PSA vaccination also strongly stimulated production of IgG2a/b anti-PSA antibodies. Tumors in vaccinated mice showed low levels of PSA expression and significant CD8+ T cell infiltration. Tumor growth in VLPV–PSA vaccinated mice was significantly delayed at early time points (p = 0.002, Gehan–Breslow test). Our data suggest that TC-83-based VLPV–PSA vaccine can efficiently overcome immune tolerance to PSA, mediate rapid clearance of PSA-expressing tumor cells and delay tumor growth. The VLPV–PSA vaccine will undergo further testing for the immunotherapy of prostate cancer. 相似文献
8.
Mikkel A. Sørensen Valdemar L. Andersen Helle Westergren Hendel Charles Vriamont Corentin Warnier Julien Masset Tri Hien Viet Huynh 《Journal of labelled compounds & radiopharmaceuticals》2020,63(8):393-403
Prostate-specific membrane antigen (PSMA)-based radioligands for positron emission tomography (PET)/computed tomography (CT) studies represent the gold standard for detection of recurrent prostate cancer (PCa). [68Ga]PSMA-HBED-CC is a PET radiotracer suitable for detection of PCa, and its clinical use has become widespread over the last few years. In this contribution, we detail our GMP-compliant production of [68Ga]PSMA-HBED-CC using the Trasis miniAllinOne radiosynthesizer and report synthetic and clinical data for the first 100 productions of 2019. Additionally, we detail our efforts towards a GMP-compliant production of the radiotherapeutic [177Lu]PSMA-I&T using the same synthesis module. PSMA-based radioligand therapy (RLT) offers a possible future treatment in cases of metastatic castration-resistant PCa, and GMP-compliant routine production methods are therefore called for. This report highlights how PSMA-based agents for theranostic purposes can be conveniently produced at a single radiochemistry Good Manufacturing Practice (GMP) site, thereby facilitating optimized detection and treatment of PCa. 相似文献
9.
10.